검색
InMed Pharmaceuticals Inc
INM관심 목록에 추가
1.460USD
-0.040-2.67%
종가 07-31 16:00（ET）시세는 15분 지연됩니다
4.09M시가총액
손실P/E TTM
자세한 내용은 InMed Pharmaceuticals Inc 회사
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Inc 정보
종목 코드 INM
회사 이름InMed Pharmaceuticals Inc
상장일Jun 21, 2001
CEOAdams (Eric A)
직원 수- -
유형Ordinary Share
회계 연도 종료Jun 21
주소1445-885 West Georgia St.
도시VANCOUVER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Canada
우편 번호V6C 3E8
전화16046697207
웹사이트https://www.inmedpharma.com/
종목 코드 INM
상장일Jun 21, 2001
CEOAdams (Eric A)
InMed Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
자주 묻는 질문
InMed Pharmaceuticals Inc의 상위 5대 주주는 누구인가요?
InMed Pharmaceuticals Inc의 상위 5대 주주는 다음과 같습니다: Mr. Andrew Harold Hull
InMed Pharmaceuticals Inc(INM)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, InMed Pharmaceuticals Inc의 주식을 보유한 기관은 총 31곳이며, 이들이 보유한 주식의 총 가치는 약 320.11K로 전체 발행 주식의 9.66%를 차지합니다. 이는 2025Q4 대비 -43643.00 증가한 수치입니다.